Company
Every investor coverage indicates participated in a round Victor Chang Cardiac Research Institute raised.
Companies Victor Chang Cardiac Research Institute acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Peter Macdonald | Professor | Startup Daily |
Stories naming Victor Chang Cardiac Research Institute. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Brisbane biotech Infensa Bioscience raised $23 million to develop a heart-attack and stroke treatment derived from funnel-web spider venom, after spinning out of the University of Queensland.